{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:48:23Z","timestamp":1790092103152,"version":"4.0.1"},"update-to":[{"DOI":"10.1002\/14651858.cd010383.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T00:00:00Z","timestamp":1616025600000}}],"reference-count":146,"publisher":"Wiley","issue":"3","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd010383.pub3","type":"journal-article","created":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T09:42:32Z","timestamp":1616060552000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer"],"prefix":"10.1002","volume":"2021","author":[{"given":"Janette","family":"Greenhalgh","sequence":"additional","affiliation":[{"name":"Liverpool Reviews and Implementation Group; University of Liverpool; Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Boland","sequence":"additional","affiliation":[{"name":"Liverpool Reviews and Implementation Group; University of Liverpool; Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Bates","sequence":"additional","affiliation":[{"name":"Liverpool Reviews and Implementation Group; University of Liverpool; Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Vecchio","sequence":"additional","affiliation":[{"name":"Liverpool Reviews and Implementation Group; University of Liverpool; Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yenal","family":"Dundar","sequence":"additional","affiliation":[{"name":"Liverpool Reviews and Implementation Group; University of Liverpool; Liverpool UK"},{"name":"Central Queensland Hospital and Health Service; Rockhampton Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marty","family":"Chaplin","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences; Liverpool School of Tropical Medicine; Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A","family":"Green","sequence":"additional","affiliation":[{"name":"Institute of Translational Medicine; University of Liverpool; Bebington UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,3,18]]},"reference":[{"issue":"6","key":"10.1002\/14651858.CD010383.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1200\/JCO.2009.25.2890","article-title":"Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane\/carboplatin in advanced non-small-cell lung cancer","volume":"28","author":"Khambata-Ford","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD010383.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1200\/JCO.2009.21.9618","article-title":"Cetuximab and first-line taxane\/carboplatin chemotherapy in advanced non-small cell lung cancer: results of the randomized multicenter phase III trial BMS099","volume":"28","author":"Lynch","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD010383.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/JTO.0b013e31823a39e8","article-title":"Phase II randomized trial of erlotinib or vinorelbine in chemonaive, advanced, non-small cell lung cancer patients aged 70 years or older","volume":"7","author":"Chen","year":"2012","journal-title":"Journal of Thoracic Oncology"},{"issue":"10","key":"10.1002\/14651858.CD010383.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1093\/annonc\/mdx359","article-title":"First-line icotinib versus cisplatin\/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study","volume":"28","author":"Shi","year":"2017","journal-title":"Annals of Oncology"},{"issue":"9","key":"10.1002\/14651858.CD010383.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/annonc\/mdv276","article-title":"First-line erlotinib versus gemcitabine\/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study","volume":"26","author":"Zhou","year":"2015","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD010383.pub3-BIB0006|cit6","first-page":"S37","article-title":"Quality of life (QOL) analysis from ENSURE, a phase 3, open-label study of first-line erlotinib versus gemcitabine\/cisplatin in Asian patients with epidermal growth factor receptor (EGFR) mutation positive (MUT+) non-small cell lung cancer (NSCLC)","volume":"9","author":"Zhou","year":"2014","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1002\/14651858.CD010383.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"S597","DOI":"10.1016\/S0959-8049(11)72328-0","article-title":"Erlotinib vs chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) activating mutations \u2212 the EURTAC Phase II randomized trial interim results","volume":"47","author":"De Marinis","year":"2011","journal-title":"European Journal of Cancer"},{"issue":"3","key":"10.1002\/14651858.CD010383.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2217\/fon.14.269","article-title":"Erlotinib-associated rash in patients with EGFR mutation-positive non-small-cell lung cancer treated in the EURTAC trial","volume":"11","author":"De Marinis","year":"2015","journal-title":"Future Oncology"},{"issue":"3","key":"10.1002\/14651858.CD010383.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD010383.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2016.04.023","article-title":"Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine\/platinum in the first-line treatment of advanced non-small-cell lung cancer","volume":"98","author":"Mok","year":"2016","journal-title":"Lung Cancer"},{"issue":"Suppl","key":"10.1002\/14651858.CD010383.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"7519","DOI":"10.1200\/jco.2012.30.15_suppl.7519","article-title":"A randomized placebo-controlled phase III study of intercalated erlotinib with gemcitabine\/platinum in first-line advanced non-small cell lung cancer (NSCLC): FASTACT-II","volume":"30","author":"Mok","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10.1002\/14651858.CD010383.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S1470-2045(13)70254-7","article-title":"Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial","volume":"14","author":"Wu","year":"2013","journal-title":"Lancet Oncology"},{"issue":"10","key":"10.1002\/14651858.CD010383.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1200\/JCO.2011.36.8456","article-title":"First-SIGNAL: first-line single-agent Iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung","volume":"30","author":"Han","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD010383.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S1470-2045(11)70189-9","article-title":"Molecular biomarkers in non-small cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study","volume":"12","author":"O'Byrne","year":"2011","journal-title":"Lancet Oncology"},{"issue":"9674","key":"10.1002\/14651858.CD010383.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S0140-6736(09)60569-9","article-title":"Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial","volume":"373","author":"Pirker","year":"2009","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD010383.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/jco.2010.28.15_suppl.7565","article-title":"Erlotinib versus carboplatin\/vinorelbine in elderly patients (age 70 or older) with advanced non-small cell lung carcinoma (NSCLC): a randomised phase II study of the German Thoracic Oncology Working Group","volume":"28","author":"Reck","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD010383.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1002\/ijc.30806","article-title":"Combination of chemotherapy and gefitinib as first-line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: a randomized controlled trial","volume":"141","author":"Han","year":"2017","journal-title":"International Journal of Cancer"},{"key":"10.1002\/14651858.CD010383.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"8081","DOI":"10.1200\/JCO.2005.02.7078","article-title":"Epidermal growth factor receptor mutations in non-small cell lung cancer: molecular analysis of the IDEAL\/INTACT gefitinib studies","volume":"23","author":"Bell","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD010383.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1200\/JCO.2004.08.001","article-title":"Gefitinib in combination with gemcitabine and cisplatin in advanced non-small cell lung cancer: a phase III trial - INTACT 1","volume":"22","author":"Giaccone","year":"2004","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD010383.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2004.07.215","article-title":"Gefitinib in combination with paclitaxel and carboplatin in advanced non-small cell lung cancer: a phase III trial - INTACT 2","volume":"22","author":"Herbst","year":"2004","journal-title":"Journal of Clinical Oncology"},{"issue":"21","key":"10.1002\/14651858.CD010383.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1200\/JCO.2010.33.4235","article-title":"Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin\/paclitaxel in clinically selected patients with advanced non-small cell lung cancer in Asia (IPASS)","volume":"29","author":"Fukuoka","year":"2011","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD010383.pub3-BIB0022|cit22","first-page":"S443","article-title":"Analyses of Japanese patients recruited in IPASS, a phase III, randomized, open-label, first-line study of gefitinib vs carboplatin\/paclitaxel in selected patients with advanced non-small cell lung cancer","volume":"4","author":"Ichinose","year":"2009","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1002\/14651858.CD010383.pub3-BIB0023|cit23","first-page":"1","article-title":"Phase III randomised open-label first-line study of gefitinib vs carboplatin\/paclitaxel in clinically selected patients with advanced non-small cell lung cancer (IPASS)","volume":"19","author":"Mok","year":"2008","journal-title":"Annals of Oncology"},{"issue":"10","key":"10.1002\/14651858.CD010383.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"New England Journal of Medicine"},{"issue":"15s","key":"10.1002\/14651858.CD010383.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"8044","DOI":"10.1200\/jco.2009.27.15_suppl.8044","article-title":"Phase III, randomized, open-label, first-line study of gefitinib versus carboplatin\/paclitaxel in selected patients with advanced non-small cell lung cancer (IPASS): evaluation of recruits in Japan","volume":"27","author":"Ohe","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"11","key":"10.1002\/14651858.CD010383.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1097\/JTO.0b013e31822adaf7","article-title":"Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin\/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS)","volume":"6","author":"Thongprasert","year":"2011","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1002\/14651858.CD010383.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.lungcan.2013.03.004","article-title":"Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: post hoc analyses from the IPASS study","volume":"81","author":"Wu","year":"2013","journal-title":"Lung Cancer"},{"issue":"15s","key":"10.1002\/14651858.CD010383.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"8041","DOI":"10.1200\/jco.2009.27.15_suppl.8041","article-title":"Evaluation of clinically selected patients with advanced non-small cell lung cancer recruited in China in a phase III, randomized, open-label, first-line study in Asia of gefitinib versus carboplatin\/paclitaxel (IPASS)","volume":"27","author":"Wu","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD010383.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1743-7563.2012.01518.x","article-title":"Phase III, randomized, open-label, first-line study in Asia of gefitinib versus carboplatin\/paclitaxel in clinically selected patients with advanced non-small cell lung cancer: evaluation of patients recruited from mainland China","volume":"8","author":"Wu","year":"2012","journal-title":"Asia-Pacific Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD010383.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.lungcan.2016.11.022","article-title":"Efficacy according to blind independent central review: post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin\/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC","volume":"104","author":"Wu","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1002\/14651858.CD010383.pub3-BIB0031|cit31","first-page":"LBA2","article-title":"Final overall survival (OS) results from a phase III, randomised, open-label, first-line study of gefitinib v carboplatin\/paclitaxel in clinically selected patients with advanced non-small cell lung cancer in Asia (IPASS)","volume":"21","author":"Yang","year":"2010","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD010383.pub3-BIB0032|cit32","unstructured":"Submission of evidence on the use of afatinib in adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating Epidermal Growth Factor Receptor (EGFR) mutation(s) www.nice.org.uk\/guidance\/TA310\/documents\/lung-cancer-non-small-cell-egfr-mutation-positive-afatinib-evaluation-report"},{"key":"10.1002\/14651858.CD010383.pub3-BIB0033|cit33","doi-asserted-by":"crossref","unstructured":"O'Byrne KJ Sequist LV Schuler M Yamamoto N Hirsh V Mok T LUX-Lung 3: symptom and health-related quality of life results from a randomized phase III study in 1st-line advanced NSCLC patients harbouring EGFR mutations 11th Annual British Thoracic Oncology Group Conference; 2013 January 23-25; Dublin Ireland 2013 S11","DOI":"10.1016\/S0169-5002(13)70032-1"},{"key":"10.1002\/14651858.CD010383.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD010383.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"LBA7500","DOI":"10.1200\/jco.2012.30.18_suppl.lba7500","article-title":"LUX-Lung 3: a randomized, open-label, phase III study of afatinib vs cisplatin\/pemetrexed as first line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations","volume":"30","author":"Yang","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD010383.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1097\/JTO.0000000000000517","article-title":"Symptom and quality of life improvement in LUX-Lung 6: an open-label phase III study of afatinib versus cisplatin\/gemcitabine in Asian patients with EGFR mutation-positive advanced non-small-cell lung cancer","volume":"10","author":"Geater","year":"2015","journal-title":"Journal of Thoracic Oncology"},{"issue":"15 (May Suppl)","key":"10.1002\/14651858.CD010383.pub3-BIB0037|cit37","first-page":"8016","article-title":"LUX-Lung 6: patient-reported outcomes (PROs) from a randomized open-label, phase III study in first-line advanced NSCLC patients harboring epidermal growth factor receptor (EGFR) mutations","volume":"31","author":"Geater","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD010383.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1470-2045(13)70604-1","article-title":"Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial","volume":"15","author":"Zhou","year":"2014","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD010383.pub3-BIB0039|cit39","first-page":"1173","article-title":"Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials","volume":"14","author":"Schuler","year":"2015","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD010383.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.lungcan.2015.02.004","article-title":"Factors associated with a poor response to gefitinib in the NEJ002 study: smoking and the L858R mutation","volume":"88","author":"Fukuhara","year":"2015","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1002\/14651858.CD010383.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1093\/annonc\/mds214","article-title":"Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-na\u00efve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)","volume":"24","author":"Inoue","year":"2012","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD010383.pub3-BIB0042|cit42","first-page":"A127","article-title":"Phase III study of gefitinib versus chemotherapy by carboplatin (CBDCA) plus paclitaxel (TXL) as first-line therapy for non-small cell lung cancer (NSCLC) with EGFR mutations: North East Japan Gefitinib Study Group Trial 002 (NEJ002)","volume":"14","author":"Kinoshita","year":"2009","journal-title":"Respirology"},{"issue":"25","key":"10.1002\/14651858.CD010383.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non-small cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD010383.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1634\/theoncologist.2011-0426","article-title":"Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial","volume":"17","author":"Oizumi","year":"2012","journal-title":"Oncologist"},{"issue":"8","key":"10.1002\/14651858.CD010383.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1097\/JTO.0b013e31821d43a8","article-title":"Low-dose gefitinib treatment for patients with advanced non-small cell lung cancer harboring sensitive epidermal growth factor receptor mutations","volume":"6","author":"Satoh","year":"2011","journal-title":"Journal of Thoracic Oncology"},{"issue":"12","key":"10.1002\/14651858.CD010383.pub3-BIB0046|cit46","first-page":"6957","article-title":"Comparison of gefitinib versus chemotherapy in patients with non-small cell lung cancer with Exon 19 deletion","volume":"35","author":"Watanabe","year":"2015","journal-title":"Anticancer Research"},{"issue":"6","key":"10.1002\/14651858.CD010383.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/annonc\/mdt012","article-title":"Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)","volume":"24","author":"Chen","year":"2013","journal-title":"Annals Oncology"},{"key":"10.1002\/14651858.CD010383.pub3-BIB0048|cit48","first-page":"1883","article-title":"First biomarker analyses from a phase III randomised open-label first-line study of erlotinib versus carboplatin plus gemcitabine in Chinese patients with advanced non-small cell lung cancer (NSCLC) with EGFR activating mutations (OPTIMAL, CTONG0802)","volume":"21","author":"Wu","year":"2010","journal-title":"Annals of Oncology"},{"issue":"15 (May Suppl)","key":"10.1002\/14651858.CD010383.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"7520","DOI":"10.1200\/jco.2012.30.15_suppl.7520","article-title":"Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC)","volume":"30","author":"Zhou","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD010383.pub3-BIB0050|cit50","first-page":"6","article-title":"Efficacy results from the randomised phase III OPTIMAL (CTONG 0802) study comparing first-line erlotinib versus carboplatin plus gemcitabine in Chinese advanced non small cell lung cancer (NSCLC) patients with EGFR activating mutations","volume":"21","author":"Zhou","year":"2010","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD010383.pub3-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1093\/annonc\/mdv276","article-title":"Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non small-cell lung cancer (OPTIMAL, CTONG-0802)","volume":"26","author":"Zhou","year":"2015","journal-title":"Annals of Oncology"},{"issue":"8","key":"10.1002\/14651858.CD010383.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation positive non-small cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD010383.pub3-BIB0053|cit53","first-page":"e000168","article-title":"Phase III study of gefitinib or pemetrexed with carboplatin in EGFR mutated advanced lung adenocarcinoma","volume":"2","author":"Patil","year":"2017","journal-title":"European Society for Medical Oncology Open"},{"issue":"11","key":"10.1002\/14651858.CD010383.pub3-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/S1470-2045(12)70412-6","article-title":"First-line erlotinib in patients with advanced non-small cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled phase III trial","volume":"13","author":"Lee","year":"2012","journal-title":"Lancet Oncology"},{"issue":"12","key":"10.1002\/14651858.CD010383.pub3-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1097\/JTO.0b013e318275b327","article-title":"Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin\/gemcitabine chemotherapy in advanced non-small cell lung cancer","volume":"7","author":"Di Maio","year":"2012","journal-title":"Journal of Thoracic Oncology"},{"issue":"4","key":"10.1002\/14651858.CD010383.pub3-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3816\/CLC.2008.n.037","article-title":"An international, multicenter, randomized phase III study of first-line erlotinib followed by second-line cisplatin\/gemcitabine versus first-line cisplatin\/gemcitabine followed by second-line erlotinib in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics of the TORCH trial","volume":"9","author":"Gridelli","year":"2008","journal-title":"Clinical Lung Cancer"},{"issue":"24","key":"10.1002\/14651858.CD010383.pub3-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1200\/JCO.2011.41.2056","article-title":"First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small cell lung cancer: the TORCH randomized trial","volume":"30","author":"Gridelli","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"34","key":"10.1002\/14651858.CD010383.pub3-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"57528","DOI":"10.18632\/oncotarget.15725","article-title":"Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients","volume":"8","author":"Kim","year":"2017","journal-title":"Oncotarget"},{"key":"10.1002\/14651858.CD010383.pub3-BIB0059|cit59","unstructured":"Tsao M Gallo S Saieg C Santos M Gebbia GDC Perrone V Biomarkers of torch trial on first-line erlotinib followed by second-line chemotherapy in advanced non-small cell lung cancer patients International Association for the Study of Lung Cancer, 3rd European Lung Cancer Conference; 2012 April 18-21; Geneva, Switzerland 2012"},{"issue":"15 (S1)","key":"10.1002\/14651858.CD010383.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"7521","DOI":"10.1200\/jco.2012.30.15_suppl.7521","article-title":"Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR)","volume":"30","author":"Mitsudomi","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD010383.pub3-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"Gefitinib versus cisplatin plus docetaxel in patients with non-small cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial","volume":"11","author":"Mitsudomi","year":"2009","journal-title":"Lancet Oncology"},{"issue":"15 (May Suppl)","key":"10.1002\/14651858.CD010383.pub3-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"8117","DOI":"10.1200\/jco.2014.32.15_suppl.8117","article-title":"Final overall survival results of WJTOG 3405, a randomized phase 3 trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer (NSCLC) harboring mutations of the epidermal growth factor receptor (EGFR)","volume":"32","author":"Yoshioka","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"12","key":"10.1002\/14651858.CD010383.pub3-BIB0063|cit63","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1093\/annonc\/mdz399","article-title":"Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB\/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer","volume":"30","author":"Yoshioka","year":"2019","journal-title":"Annals of Oncology"},{"issue":"7","key":"10.1002\/14651858.CD010383.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"832","DOI":"10.4161\/cbt.28874","article-title":"A phase II randomized trial evaluating gefitinib intercalated with pemetrexed\/platinum chemotherapy or pemetrexed\/platinum chemotherapy alone in unselected patients with advanced non-squamous non-small cell lung cancer","volume":"15","author":"Yu","year":"2014","journal-title":"Cancer Biology & Therapy"},{"key":"10.1002\/14651858.CD010383.pub3-BIB0065|cit65","first-page":"125","article-title":"Docetaxel-carboplatin in combination with erlotinib and\/or bevacizumab in patients with non-small cell lung cancer","volume":"6","author":"Boutsikou","year":"2013","journal-title":"OncoTargets and Therapy"},{"issue":"26","key":"10.1002\/14651858.CD010383.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1200\/JCO.2007.15.0672","article-title":"Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study","volume":"26","author":"Crin\u00f2","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"15 (S1)","key":"10.1002\/14651858.CD010383.pub3-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"8106","DOI":"10.1200\/jco.2013.31.15_suppl.8106","article-title":"Exploratory biomarker analyses from ECOG 4508: three-arm randomized phase II study of carboplatin (C) and paclitaxel (P) in combination with cetuximab (CET), IMC-A12, or both for advanced non-small cell lung cancer (NSCLC) patients (pts)","volume":"31","author":"Aggarwal","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"30","key":"10.1002\/14651858.CD010383.pub3-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"5080","DOI":"10.1200\/JCO.2008.21.5541","article-title":"Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer","volume":"27","author":"Mok","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD010383.pub3-BIB0069|cit69","first-page":"642","article-title":"Cetuximab (C225) in combination with cisplatin\/vinorelbine vs. cisplatin\/vinorelbine alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR) positive advanced non-small cell lung cancer (NSCLC)","volume":"22","author":"Gatzemeier","year":"2003","journal-title":"Journal of Clinical Oncology"},{"issue":"13","key":"10.1002\/14651858.CD010383.pub3-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1200\/JCO.2008.18.4408","article-title":"Randomized phase II study of gefitinib compared with placebo in chemotherapy-naive patients with advanced non-small cell lung cancer and poor performance status","volume":"27","author":"Goss","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD010383.pub3-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.lungcan.2014.01.024","article-title":"Open, randomized, multi-center phase II study comparing efficacy and tolerability of erlotinib vs. carboplatin\/vinorelbin in elderly patients (> 70 years of age) with untreated non-small cell lung cancer","volume":"84","author":"Heigener","year":"2014","journal-title":"Lung Cancer"},{"issue":"26","key":"10.1002\/14651858.CD010383.pub3-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1200\/JCO.2010.34.4929","article-title":"A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer","volume":"29","author":"Hirsch","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"17","key":"10.1002\/14651858.CD010383.pub3-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1200\/JCO.2011.40.1315","article-title":"Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB30406 trial","volume":"30","author":"J\u00e4nne","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"11","key":"10.1002\/14651858.CD010383.pub3-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/S1470-2045(14)70381-X","article-title":"Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study","volume":"15","author":"Seto","year":"2014","journal-title":"Lancet Oncology"},{"issue":"6","key":"10.1002\/14651858.CD010383.pub3-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1200\/JCO.2007.13.2720","article-title":"Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small cell lung cancer and a performance status of 2","volume":"26","author":"Lilenbaum","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD010383.pub3-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"TPS8127","DOI":"10.1200\/jco.2014.32.15_suppl.tps8127","article-title":"Open, phase II randomized trial of gefitinib alone versus olaparib (AZD2281) plus gefitinib in advanced non-small cell lung cancer (NSCLC) patients (P) with epidermal growth factor receptor (EGFR) mutations: Spanish Lung Cancer Group trial","volume":"32","author":"Massuti","year":"2014","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD010383.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"V56","DOI":"10.1093\/annonc\/mdu435.52","article-title":"Randomized PII of concurrent vs sequential alternating gefitinib and chemotherapy in EGFR-mutant NSCLC: NEJ005\/TCOG0902","volume":"25","author":"Minato","year":"2014","journal-title":"Annals of Oncology"},{"issue":"15","key":"10.1002\/14651858.CD010383.pub3-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"8016","DOI":"10.1200\/jco.2014.32.15_suppl.8016","article-title":"Randomized phase II study of concurrent gefitinib and chemotherapy versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer (NSCLC) with sensitive EGFR mutations: NEJ005\/TCOG0902","volume":"32","author":"Oizumi","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD010383.pub3-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1093\/annonc\/mdv063","article-title":"Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005\/TCOG0902","volume":"26","author":"Sugawara","year":"2015","journal-title":"Annals of Oncology"},{"issue":"15","key":"10.1002\/14651858.CD010383.pub3-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"TPS8131","DOI":"10.1200\/jco.2014.32.15_suppl.tps8131","article-title":"NEJ009 trial: a randomized phase III study of gefitinib (G) in combination with carboplatin (C) plus pemetrexed (P) versus G alone in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) with EGFR mutation","volume":"32","author":"Inoue","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"14S","key":"10.1002\/14651858.CD010383.pub3-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"7012","DOI":"10.1200\/jco.2004.22.90140.7012","article-title":"Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing advanced non-small cell lung cancer (NSCLC)","volume":"22","author":"Rosell","year":"2004","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD010383.pub3-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"362-9","DOI":"10.1093\/annonc\/mdm474","article-title":"Randomized phase II study of cetuximab plus cisplatin\/vinorelbine compared with cisplatin\/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small cell lung cancer","volume":"19","author":"Rosell","year":"2008","journal-title":"Annals of Oncology"},{"issue":"15","key":"10.1002\/14651858.CD010383.pub3-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"8008","DOI":"10.1200\/jco.2014.32.15_suppl.8008","article-title":"A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) chemotherapy plus necitumumab (IMC-11F8\/LY3012211) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC)","volume":"32","author":"Thatcher","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD010383.pub3-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/ajco.12178","article-title":"Multicenter randomized, open-label phase II trial of sequential erlotinib and gemcitabine compared with gemcitabine monotherapy as first-line therapy in elderly or ECOG PS two patients with advanced NSCLC","volume":"11","author":"Michael","year":"2015","journal-title":"Asia-Pacific Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD010383.pub3-BIB0085|cit85","first-page":"446","article-title":"Gefitinib versus erlotinib as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer","volume":"35","author":"Xie","year":"2015","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao"},{"issue":"1","key":"10.1002\/14651858.CD010383.pub3-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s13063-015-0685-2","article-title":"Fuzheng Kang'ai decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: study protocol for a randomized controlled trial","volume":"16","author":"Yang","year":"2015","journal-title":"Trials"},{"issue":"12","key":"10.1002\/14651858.CD010383.pub3-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1200\/JCO.2005.05.1474","article-title":"Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small cell lung cancer: the Tarceva Lung Cancer Investigation trial","volume":"25","author":"Gatzmeier","year":"2007","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD010383.pub3-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"5892","DOI":"10.1200\/JCO.2005.02.840","article-title":"TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small cell lung cancer","volume":"25","author":"Herbst","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD010383.pub3-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"e54170","DOI":"10.1371\/journal.pone.0054170","article-title":"Detection and clinical significance of intratumoral EGFR mutational heterogeneity in Chinese patients with advanced non-small cell lung cancer","volume":"8","author":"Bai","year":"2013","journal-title":"PLOS One"},{"issue":"10","key":"10.1002\/14651858.CD010383.pub3-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1200\/JCO.2011.38.7571","article-title":"Progression-free survival: meaningful or simply measurable?","volume":"30","author":"Booth","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"31","key":"10.1002\/14651858.CD010383.pub3-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta17060","article-title":"Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation","volume":"17","author":"Brown","year":"2013","journal-title":"Health Technology Assessment"},{"key":"10.1002\/14651858.CD010383.pub3-BIB0092|cit92","unstructured":"Cancer Research UK Lung cancer incidence www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/lung-cancer#heading-Zero"},{"key":"10.1002\/14651858.CD010383.pub3-BIB0093|cit93","unstructured":"Cancer Rearch UK Lung cancer incidence statistics www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/lung-cancer#heading-Zerowww.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/lung-cancer#heading-Zero"},{"key":"10.1002\/14651858.CD010383.pub3-BIB0094|cit94","unstructured":"Cancer Research UK Lung cancer mortality statistics www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/lung-cancer\/mortality"},{"key":"10.1002\/14651858.CD010383.pub3-BIB0095|cit95","unstructured":"Cancer Research UK Lung cancer incidence by morphology about-cancer.cancerresearchuk.org\/about-cancer\/lung-cancer\/stages-types-grades\/types?_ga=2.235353729.1634280933.1587130128-852209561.1582902408"},{"key":"10.1002\/14651858.CD010383.pub3-BIB0096|cit96","unstructured":"Cancer Research UK Lung cancer risk factors www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/lung-cancer#heading-Three:\/\/www.cancerresearchuk.org\/cancer-info\/cancerstats\/types\/lung\/riskfactors\/"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD010383.pub3-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Planchard","year":"2018","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD010383.pub3-BIB0098|cit98","unstructured":"Erlotinib www.fda.gov\/drugs\/informationondrugs\/approveddrugs\/ucm352317.htm"},{"key":"10.1002\/14651858.CD010383.pub3-BIB0099|cit99","unstructured":"Afatinib www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm360574.htm"},{"key":"10.1002\/14651858.CD010383.pub3-BIB0100|cit100","unstructured":"FDA approves osimertinib for first-line treatment of metastatic NSCLC with most common EGFR mutations www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-osimertinib-first-line-treatment-metastatic-nsclc-most-common-egfr-mutations"},{"key":"10.1002\/14651858.CD010383.pub3-BIB0101|cit101","unstructured":"FDA approves dacomitinib for metastatic non-small cell lung cancer www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-dacomitinib-metastatic-non-small-cell-lung-cancer"},{"issue":"2","key":"10.1002\/14651858.CD010383.pub3-BIB0102|cit102","first-page":"113","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Ohe","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD010383.pub3-BIB0103|cit103","unstructured":"International Agency for Research on Cancer GLOBOCAN 2018: Estimated cancer incidence, mortality and prevalence worldwide in 2018 gco.iarc.fr\/today\/data\/factsheets\/cancers\/15-Lung-fact-sheet.pdf"},{"key":"10.1002\/14651858.CD010383.pub3-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"GRADE Working Group","year":"2004","journal-title":"BMJ"},{"issue":"6","key":"10.1002\/14651858.CD010383.pub3-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1097\/JTO.0000000000000156","article-title":"Meta-analysis of first-line therapies in advanced non-small-cell lung cancer harboring EGFR-activating mutations","volume":"9","author":"Haaland","year":"2014","journal-title":"Journal of Thoracic Oncology"},{"issue":"2","key":"10.1002\/14651858.CD010383.pub3-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.canlet.2012.01.011","article-title":"Landscape of EGFR signalling network in human cancer","volume":"318","author":"Han","year":"2012","journal-title":"Cancer Letters"},{"issue":"11","key":"10.1002\/14651858.CD010383.pub3-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1097\/JTO.0b013e31822722b6","article-title":"Ethnic difference in haematological toxicity in patients with non-small-cell lung cancer treated with chemotherapy: a pooled analysis on Asian versus non-Asian in phase II and III clinical trials","volume":"6","author":"Hasegawa","year":"2011","journal-title":"Journal of Thoracic Oncology"},{"issue":"3","key":"10.1002\/14651858.CD010383.pub3-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1634\/theoncologist.2014-0285","article-title":"The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomized trials","volume":"20","author":"Hasegawa","year":"2015","journal-title":"Oncologist"},{"key":"10.1002\/14651858.CD010383.pub3-BIB0109|cit109","unstructured":"Higgins JPT Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from training.cochrane.org\/handbook\/archive\/v5.1"},{"key":"10.1002\/14651858.CD010383.pub3-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/jrsm.1044","article-title":"Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies","volume":"3","author":"Higgins","year":"2012","journal-title":"Research Synthesis Methods"},{"key":"10.1002\/14651858.CD010383.pub3-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1200\/JCO.2009.25.2890","article-title":"Analysis of potential predictive markers of cetuximab benefit in BMS099, a Phase III study of cetuximab and first-line taxane\/carboplatin in advanced non small cell lung cancer","volume":"28","author":"Khambata-Ford","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD010383.pub3-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/cas.12996","article-title":"Not all epidermal growth factor receptor mutations are created equal","volume":"107","author":"Kobayashi","year":"2016","journal-title":"Cancer Science"},{"key":"10.1002\/14651858.CD010383.pub3-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"5764","DOI":"10.1158\/1078-0432.CCR-06-0714","article-title":"Analysis of epidermal growth factor receptor gene mutation in patients with non-small-cell-lung cancer and acquired resistance to gefitinib","volume":"12","author":"Kosaka","year":"2006","journal-title":"Clinical Cancer Research"},{"key":"10.1002\/14651858.CD010383.pub3-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.lungcan.2011.04.008","article-title":"Gefitinib vs chemotherapy as first-line therapy in advanced non-small cell lung cancer: meta- analysis of phase III trials","volume":"74","author":"Ku","year":"2011","journal-title":"Lung Cancer"},{"key":"10.1002\/14651858.CD010383.pub3-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1093\/jnci\/djt072","article-title":"Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis","volume":"105","author":"Lee","year":"2013","journal-title":"Journal of the National Cancer Institute"},{"issue":"17","key":"10.1002\/14651858.CD010383.pub3-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1200\/JCO.2014.58.1736","article-title":"Impact of specific epidermal growth factor receptor mutations and clinical characteristics on outcomes after treatment with EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR-mutant lung cancer: a meta-analysis","volume":"33","author":"Lee","year":"2015","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD010383.pub3-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"e85245","DOI":"10.1371\/journal.pone.0085245","article-title":"Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations","volume":"9","author":"Liang","year":"2014","journal-title":"PLOS One"},{"issue":"10","key":"10.1002\/14651858.CD010383.pub3-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/S1470-2045(08)70206-7","article-title":"Assessment of somatic k-ras mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer","volume":"9","author":"Linardou","year":"2008","journal-title":"Lancet Oncology"},{"issue":"4","key":"10.1002\/14651858.CD010383.pub3-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1056\/NEJMoa0800668","article-title":"Detection of mutations in EGFR in circulating lung-cancer cells","volume":"359","author":"Maheswaran","year":"2008","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD010383.pub3-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1136\/bmj.311.7010.899","article-title":"Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials","volume":"311","author":"Non-Small Cell Lung Collaborative Group","year":"1995","journal-title":"BMJ"},{"issue":"7447","key":"10.1002\/14651858.CD010383.pub3-BIB0121|cit121","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature12065","article-title":"Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA","volume":"497","author":"Murtaza","year":"2013","journal-title":"Nature"},{"key":"10.1002\/14651858.CD010383.pub3-BIB0122|cit122","unstructured":"Royal College of Physicians National Lung Cancer Audit. Spotlight on molecular testing www.rcplondon.ac.uk\/projects\/outputs\/spotlight-audit-molecular-testing-advanced-lung-cancer-2019-diagnoses-2017"},{"key":"10.1002\/14651858.CD010383.pub3-BIB0123|cit123","unstructured":"National Institute for Health and Care Excellence TA192: Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer www.nice.org.uk\/TA192"},{"key":"10.1002\/14651858.CD010383.pub3-BIB0124|cit124","unstructured":"National Institute for Health and Care Excellence Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer publications.nice.org.uk\/erlotinib-for-the-first-line-treatment-of-locally-advanced-or-metastatic-egfr-tk-mutation-positive-ta258"},{"key":"10.1002\/14651858.CD010383.pub3-BIB0125|cit125","unstructured":"National Institute for Health and Care Excellence Lung cancer (non small cell, EGFR mutation positive) - afatinib: final appraisal determination document guidance.nice.org.uk\/TAG\/341\/FAD\/FinalAppraisalDetermination\/pdf\/English"},{"key":"10.1002\/14651858.CD010383.pub3-BIB0126|cit126","unstructured":"Clinical Effectiveness and Evaluation Unit National Lung Cancer Audit www.hqip.org.uk\/public\/cms\/253\/625\/19\/354\/2015-12-02%20National%20Lung%20Cancer%20Report.pdf?realName=9wvAlU.pdf&v=0"},{"key":"10.1002\/14651858.CD010383.pub3-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1093\/annonc\/mds226","article-title":"Metastatic non-small cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"23 Suppl 7","author":"Peters","year":"2012","journal-title":"Annals of Oncology"},{"issue":"8","key":"10.1002\/14651858.CD010383.pub3-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"21","DOI":"10.7748\/cnp2012.10.11.8.21.c9355","article-title":"Why novel treatments require changes in disease management","volume":"11","author":"Pilkington","year":"2012","journal-title":"Cancer Nursing Practice"},{"key":"10.1002\/14651858.CD010383.pub3-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.lungcan.2013.11.006","article-title":"Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer","volume":"83","author":"Pirker","year":"2014","journal-title":"Lung Cancer"},{"issue":"10","key":"10.1002\/14651858.CD010383.pub3-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa0904554","article-title":"Screening for epidermal growth factor receptor mutations in lung cancer","volume":"361","author":"Rosell","year":"2009","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD010383.pub3-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1158\/1078-0432.CCR-10-2158","article-title":"Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small cell lung cancer patients with EGFR mutations","volume":"17","author":"Rosell","year":"2011","journal-title":"Clinical Cancer Research"},{"issue":"3","key":"10.1002\/14651858.CD010383.pub3-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small cell lung cancer (EURTAC): a multicentre, open-label, randomized phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD010383.pub3-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.jclinepi.2008.10.001","article-title":"A case study of multiple-treatments meta-analysis demonstrates that covariates should be considered","volume":"62","author":"Salanti","year":"2009","journal-title":"Journal of Clinical Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD010383.pub3-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD010383.pub3-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMoa011954","article-title":"Comparison of four chemotherapy regimens for advanced non-small cell lung cancer","volume":"346","author":"Schiller","year":"2002","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD010383.pub3-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1183\/09031936.00097311","article-title":"Prognostic value of TP53, KRAS and EGFR mutations in non-small cell lung cancer: EUELC cohort","volume":"40","author":"Scoccianti","year":"2012","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD010383.pub3-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.lungcan.2013.11.016","article-title":"Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: a systematic review and meta-analysis of clinical trials","volume":"83","author":"Shi","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1002\/14651858.CD010383.pub3-BIB0138|cit138","first-page":"3224","article-title":"Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small cell lung cancer","volume":"38","author":"Su","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD010383.pub3-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2353\/jmoldx.2010.090188","article-title":"Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications","volume":"12","author":"Tsiatis","year":"2010","journal-title":"Journal of Molecular Diagnostics"},{"issue":"1","key":"10.1002\/14651858.CD010383.pub3-BIB0140|cit140","first-page":"147","article-title":"Assessment of EGFR and K-ras mutations in fixed and fresh specimens from transesophageal ultrasound-guided fine needle aspiration in non-small cell lung cancer patients","volume":"41","author":"Ulivi","year":"2012","journal-title":"International Journal of Oncology"},{"key":"10.1002\/14651858.CD010383.pub3-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1126\/science.1235122","article-title":"Cancer genome landscapes","volume":"339","author":"Vogelstein","year":"2013","journal-title":"Science"},{"key":"10.1002\/14651858.CD010383.pub3-BIB0142|cit142","first-page":"5s","article-title":"Overall survival (OS) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19\/L858R) epidermal growth factor receptor mutations (EGFR mut): pooled analysis of two large open-label phase III studies (LUX-Lung 3 [LL3] and LUX-Lung 6 [LL6]) comparing afatinib with chemotherapy (CT)","volume":"32","author":"Sequist","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10.1002\/14651858.CD010383.pub3-BIB0143|cit143","first-page":"735","article-title":"EGFR exon 20 insertion mutations in non-small cell lung cancer","volume":"12","author":"Yasuda","year":"2011","journal-title":"Lancet Oncology"},{"issue":"4","key":"10.1002\/14651858.CD010383.pub3-BIB0144|cit144","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010383","article-title":"First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer","author":"Green","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD010383.pub3-BIB0145|cit145","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010383.pub2","article-title":"First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer","author":"Greenhalgh","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD010383.pub3-BIB0146|cit146","unstructured":"National Institute for Health Care Excellence (NICE) Dacomitinib for untreated EGFR mutation positive non-small cell lung cancer www.nice.org.uk\/guidance\/ta595#"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T09:20:50Z","timestamp":1654593650000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD010383.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Lung Cancer Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,3,18]]},"references-count":146,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd010383.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,18]]}}}